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Ugandan stakeholder hopes and concerns 
about gene drive mosquitoes for malaria 
control: new directions for gene drive risk 
governance
Sarah Hartley1* , Robert D. J. Smith2, Adam Kokotovich3, Chris Opesen4, Tibebu Habtewold5, 
Katie Ledingham1, Ben Raymond6 and Charles B. Rwabukwali4 
Abstract 
Background: The African Union’s High-Level Panel on Emerging Technologies identified gene drive mosquitoes as a 
priority technology for malaria elimination. The first field trials are expected in 5–10 years in Uganda, Mali or Burkina 
Faso. In preparation, regional and international actors are developing risk governance guidelines which will deline-
ate the framework for identifying and evaluating risks. Scientists and bioethicists have called for African stakeholder 
involvement in these developments, arguing the knowledge and perspectives of those people living in malaria-
afflicted countries is currently missing. However, few African stakeholders have been involved to date, leaving a 
knowledge gap about the local social-cultural as well as ecological context in which gene drive mosquitoes will be 
tested and deployed. This study investigates and analyses Ugandan stakeholders’ hopes and concerns about gene 
drive mosquitoes for malaria control and explores the new directions needed for risk governance.
Methods: This qualitative study draws on 19 in-depth semi-structured interviews with Ugandan stakeholders in 
2019. It explores their hopes for the technology and the risks they believed pertinent. Coding began at a workshop 
and continued through thematic analysis.
Results: Participants’ hopes and concerns for gene drive mosquitoes to address malaria fell into three themes: (1) 
ability of gene drive mosquitoes to prevent malaria infection; (2) impacts of gene drive testing and deployment; and, 
(3) governance. Stakeholder hopes fell almost exclusively into the first theme while concerns were spread across 
all three. The study demonstrates that local stakeholders are able and willing to contribute relevant and important 
knowledge to the development of risk frameworks.
Conclusions: International processes can provide high-level guidelines, but risk decision-making must be grounded 
in the local context if it is to be robust, meaningful and legitimate. Decisions about whether or not to release gene 
drive mosquitoes as part of a malaria control programme will need to consider the assessment of both the risks and 
the benefits of gene drive mosquitoes within a particular social, political, ecological, and technological context. Just 
as with risks, benefits—and importantly, the conditions that are necessary to realize them—must be identified and 
debated in Uganda and its neighbouring countries.
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Background
Gene drive mosquitoes are an important emerging tech-
nology for vector control. The yearly downturn trend in 
malaria cases and deaths has plateaued since 2015 [1]. 
This stagnation in control is caused by insufficient cov-
erage with insecticide-treated nets and indoor residual 
spraying as well as selection for mosquito populations 
that mediate outdoor malaria transmission and the 
prominence emergence of vectors with multiple insec-
ticide resistance [1]. Gene drive mosquitoes may be an 
additional tool to complement nets and spraying by 
blocking the transmission of Plasmodium to humans. In 
2020, the African Union’s High-Level Panel on Emerging 
Technologies singled out gene drive mosquitoes as one 
of three priority technologies to contribute to malaria 
elimination [2]. The complexity of gene drive technology, 
its reliance on the rapid spread of genetically engineered 
elements and its potential to persist in environments 
and transform ecologies means that this topic is receiv-
ing increased attention in the social and natural sciences 
[3–6]. The first field trials of gene drive mosquitoes are 
expected in 5–10 years in Uganda, Mali or Burkina Faso 
[7, 8]. These mosquitoes are likely to be the first gene 
drive organisms field-tested anywhere in the world and, 
therefore, place a spotlight on scientific developments 
and risk governance in sub-Saharan Africa.
A gene drive is a mechanism that increases the fre-
quency of a desired gene in a mosquito population by 
increasing the rate at which it is spread through repro-
duction [9]. Combining gene drive with genome edit-
ing techniques, scientists are able to genetically modify 
the Anopheles mosquito genome and push modifica-
tions through the natural mosquito population to either 
suppress the population or replace it with genetically 
engineered mosquitoes [10]. This contrasts with many 
genetically engineered products in which the spread of 
genetically engineered constructs in a target species is 
generally unwelcome.
Existing risk governance frameworks for genetically 
engineered organisms seek to avoid the environmental 
spread of introduced genes. This means that in order to 
prepare for field trials of gene drive mosquitoes, existing 
risk and regulation frameworks need to be evaluated and 
it is likely that risk governance guidelines must be devel-
oped or modified. Traditional field trials, which rely on 
controlled releases in specific geographical sites, will be 
difficult as gene drive constructs are designed to spread 
rapidly and may not respect the boundaries of a trial site 
[11]. The gene drive developer community, made up of 
researchers, funders, supporters, regulators and policy-
makers, has begun to delineate a governance framework, 
identifying potential risks arising from the development, 
testing and possible deployment of gene drive mosqui-
toes and determining how to manage them. These efforts 
involve expert workshops, meetings, academic papers 
and draft guidance [7, 12–14].
Scientists and bioethicists have raised concerns about 
the small number of African scientists, stakeholders and 
publics involved with gene drive mosquito development 
and governance [4, 15]. Echoing these concerns, Afri-
can scientists have called for the involvement of a broad 
range of African scientists and stakeholders in conversa-
tions about gene drive mosquitoes for malaria control 
[16, 17]. African policy-makers have joined these calls, 
arguing that the knowledge and perspectives of those 
people living in malaria-afflicted countries is missing in 
such conversations [17, 18]. Lastly, bioethicists argue that 
ethical debate about whether to release gene drive mos-
quitoes in field trials should include African stakeholders 
living in malaria endemic areas [15].
Despite these calls for the involvement of African sci-
entists, stakeholders and communities in gene drive 
development and governance, very few efforts to develop 
risk governance frameworks have actively sought to 
engage African publics. Many workshops to explore 
risks of releasing gene drive mosquitoes in Africa have 
engaged European or American stakeholders [7]. Even 
where international workshops were designed to explore 
potential risks related gene drive mosquitoes for malaria 
control in sub-Saharan Africa, African participants were 
largely absent in comparison to European and American 
participants (Europe/USA = 34, Africa = 8, Asia/South 
America = 3, WHO = 2) [12]. One of the few exceptions 
was a series of four regional consultations organized by 
the New Partnership for Africa’s Development and held 
in Ghana, Kenya, Botswana, and Gabon during 2016–
2018 [6]. Here, African stakeholders identified similar 
protection goals and harm pathways to American stake-
holders at an earlier workshop in 2016 but also raised 
new concerns about mosquito behavior and fresh water 
protection goals [6].
The very limited African input into decisions about 
how to govern gene drive mosquitoes for malaria con-
trol has led to explicit calls for empowering and engaging 
African stakeholders who understand the local health, 
social-cultural as well as ecological context [12]. Neves 
Keywords: Malaria control, Gene drive mosquitoes, Uganda, Stakeholders, Risk governance, Risk assessment, Target 
Malaria
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and Druml [15] emphasize the importance of ‘reflecting 
on the risks and benefits for people living in areas endemic 
for malaria’. Engaging with African publics is likely to 
bring substantive insights to risk governance which may 
not be identified by other actors [19]. It may also improve 
the value of risk governance by making it meaningful and 
informative [7]. Situating engagement in the local con-
text is essential for risk governance, not only to capture 
the specific technology application being used and the 
receiving environment, but to ensure that local political 
context and local values inform the many value judg-
ments inherent to the risk governance process [20, 21]. 
Taitingfong has argued:
“Because concepts such as risk and benefit are con-
tingent upon the communities or persons defining 
them, it is important that decisions surrounding 
gene drive do not rely solely on extant frameworks 
that will inevitably omit culturally specific consid-
erations, including those of indigenous groups” [22].
Gene drive technology’s unique risks (namely, to 
spread throughout a population, persist in the environ-
ment, and cause irreversible effects) and ethical concerns 
about developers from high-income countries shaping 
risk governance frameworks in low- and middle-income 
countries further compel the need to ensure that contex-
tually-specific values, knowledge, hopes and concerns 
feed into the development of risk frameworks. This lack 
of knowledge about what questions need asking and how 
they are answered in relation to the local context for 
governance of gene drive mosquitoes presents a critical 
gap. This study brings the local context to bear on this 
promissory technology for malaria control by investigat-
ing and analyzing the hopes and concerns that matter for 
Ugandan stakeholders and mapping out the new direc-




Uganda has one of the highest incidences of malaria 
in the world and malaria remains the leading cause of 
death [23, 24]. Currently, malaria is controlled in Uganda 
through indoor residual spraying, drug treatments and 
the provision of free insecticide-treated bed nets—the 
Ministry of Health recently launched a new univer-
sal campaign to distribute over 27 million nets across 
Uganda [25]. However, the ongoing pervasiveness of the 
disease points to the need to consider innovative solu-
tions as part of a broader toolkit for malaria control. Tar-
get Malaria, a multinational research consortium funded 
largely by the Bill and Melinda Gates Foundation (BMGF) 
(US$75 million) and the Open Philanthropy Project 
(US$17.5 million), is expected to conduct the world’s first 
gene drive trial in Uganda, Mali and/or Burkina Faso [8]. 
Target Malaria’s Ugandan team is based at the Uganda 
Virus Research Institute (UVRI), a medical research insti-
tute located in Entebbe and known for its entomological 
expertise. Target Malaria has allocated funds to build sci-
entific capacity and a new insectary at UVRI. Mosquitoes 
are collected from villages on islands in Lake Victoria 
and in Mukono and Kayunga districts to provide base-
line research data and Target Malaria now has regulatory 
approval for importation and contained use of gene drive 
mosquitoes in Uganda [10].
Uganda is a signatory to the Convention on Biologi-
cal Diversity and the Cartagena Protocol on Biosafety. 
In 2018, the Parliament passed the Genetic Engineering 
Regulatory Bill which contains a strict clause on liability 
and redress to hold gene drive developers liable if harm 
results from field trials. However, in 2019, the President 
announced his refusal to assent to the Bill for the second 
time, explicitly mentioning genetically modified mos-
quitoes and citing several concerns about safeguard-
ing citizens and the ecology stating that ‘commercial 
interests, however, need to be balanced against the need 
to protect the ordinary Ugandan Citizen from real and 
potential harm, health and wellbeing rather than profit, 
must be our primary concern’ [26]. When Target Malaria 
is ready for field trials, it will seek approval from the 
National Environmental Management Authority, Uganda 
Virus Research Institute Biosafety Committee, National 
Biosafety Committee at the Ugandan National Coun-
cil for Science and Technology, and National Bioethics 
Committee at the Ministry of Science, Technology and 
Innovation. Regionally, the BMGF and the Open Philan-
thropy Project, Target Malaria’s funders, provide consid-
erable funds to the African Union Development Agency 
(AUDA) to build regulatory research capacity in Africa 
and prepare for the testing and deployment of gene 
drive mosquitoes for malaria control [27, 28]. AUDA is 
committed to developing a harmonized approach to 
regulation and provides significant support to national 
regulators in collaboration with Target Malaria. Its goal 
is to ‘create enabling regulatory environments that allow 
science, technology and innovation to thrive’ explicitly for 
malaria control applications [29].
Data collection
Data was collected between August and December 2019 
using semi-structured interviews with 19 key Ugandan 
actors including one social scientist, four entomologists/
biotech experts, two medical doctors, one veterinary 
doctor, two representatives of the community and/or 
members of the vulnerable and marginalized groups liv-
ing near to UVRI, five biotechnology experts, one legal 
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expert, one environmentalist and two biosafety experts. 
Participants were selected for their knowledge of, or 
experience with gene drive mosquitoes for malaria con-
trol and/or Uganda’s governance framework for this tech-
nology. Individuals from a breadth of backgrounds were 
included to capture a comprehensive range of perspec-
tives and interests. For example, two participants claimed 
to be opponents of gene drive, eight were proponents and 
seven were self-identified as neutral.
Following established social science methods, inter-
views were semi-structured and structured around the 
following questions: What hopes do you have for this 
technology?; What concerns do you have about this tech-
nology? Interviews explored participants’ hopes for the 
technology, the concerns they believed pertinent, and 
the ways in which these concerns might be addressed 
[30]. Due to the contentious nature of biotechnology in 
Uganda, some participants felt reluctant to engage and 
considerable effort was placed on building trust prior to 
and in the course of the interview. Some targeted par-
ticipants in regulatory institutions were not cleared to 
participate in the interviews and others kept postponing 
appointments until the study ended. While most inter-
views were recorded and transcribed, a few participants 
refused permission for their interview to be recorded. 
Here, detailed notes were taken instead. The research 
received ethical approval by Makerere University Social 
Sciences Research and Ethics Committee (MAKSS REC 
05.19.300) and National Biosafety Committee of the 
Uganda National Council for Science and Technology 
(SS5059). All participants provided consent to the use of 
anonymous quotes in research outputs.
Data analysis
Initial, explorative, analysis was conducted at an inter-
disciplinary coding workshop in December 2019 in the 
UK and comprising all authors. Following the workshop, 
four authors (SH, RS, AK, CO) coded the transcripts the-
matically [31]. All portions of text were extracted using 
the phrase ‘hopes and concerns associated with gene drive 
development and deployment’ as a heuristic to guide the 
data reduction process. Similar terms such as ‘risk and 
benefit’ were deliberately not chosen to guide this process 
to avoid imposing external categories and meanings onto 
participants’ discourse. Data were organized into coher-
ent categories, ultimately resulting in the three overarch-
ing themes. To ensure consistency in coding, two coders 
(RS and SH) completed the process individually and 
divergences were discussed and revised. The outcomes of 
the coding process were then presented to the remaining 
pair of the analysis group (AK and CO) to ensure coher-
ence and comprehensiveness.
Results
Stakeholders’ hopes and concerns about gene drive 
mosquitoes
Participants’ hopes and concerns for gene drive mos-
quitoes to address malaria fell into three broad themes: 
(1) ability of gene drive mosquitoes to address malaria, 
highlighting the importance of efficacy; (2) impacts of 
gene drive testing and deployment, highlighting the 
consequences associated with gene drive development 
and use; and, (3) governance, which is concerned with 
the processes of governing and developing the tech-
nology democratically. Stakeholder hopes fell almost 
exclusively into the first theme while concerns were 
spread across all three. Table  1 summarizes these 
findings. Each of these three themes and their sub-
themes  are presented below and illustrated with par-
ticipant quotes.
Theme 1: Ability of gene drive mosquitoes to address malaria
The overwhelming hope stakeholders identified was to 
reduce or eliminate malaria. Within this theme, two 
sub-themes emerged. The most frequent is that gene 
drive mosquitoes are effective at reducing malaria (U1–
U11, U14–U18):
“We are all optimistic that this will succeed and we 
shall have a big breakthrough in reducing malaria 
transmission in all the malaria endemic countries.” 
(U2)
Participants highlighted the significant burden of 
malaria in Uganda noting it is one of the biggest killers of 
children, women and others in Uganda and across Africa:
“Malaria’s been our biggest killer. Our children, 
our women, our people.” (U6)
Some participants imagined that gene drive mosquitoes 
could eliminate malaria and result in a type of utopia:
“If there’s no malaria being reported in a cer-
tain municipality where the mosquitoes are being 
released, for a period of six months, then the people 
will say, ‘Hey, what is so special about that munici-
pality?’ Then everyone will know, ‘Oh, they released 
genetically-modified mosquitoes.’ People will start 
talking that, ‘Oh, actually, now I’m having good 
nights. I’m not being bitten by mosquitoes anymore. 
We used to buy chemical pesticides, we used to buy 
coils to smoke the house, we used to go to the hos-
pital every now and then – now we are not going.’ 
Statistics in hospitals will show that there’s no more 
malaria, and what else do you want in life? That’s 
the perfect environment you would like to stay.” (U9)
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Other participants noted the possible increase in 
vector-borne diseases as a result of climate change 
and hoped that gene drive mosquitoes could also be an 
adaptation tool:
“Malaria is a very big issue in Uganda and having 
something which can actually prevent the multipli-
cation of mosquitoes may have a big impact in try-
ing to reduce the cases of malaria, and also there 
is the issue of climate change - we expect increased 
temperatures and maybe new types of malaria and 
the mosquitoes that migrate and perhaps evolve.” 
(U7)
The second sub-theme of hopes is that gene drive 
mosquitoes are another possible tool in the fight against 
malaria (U1-U6, U8-U9, U18-19). Some participants 
argued that gene drive mosquitoes might be better than 
some of the alternatives because they are expected to 
be low cost (U2), while others believed gene drive mos-
quitoes are more targeted on the vector than alterna-
tives and therefore better at reducing malaria:
“Instead of addressing the problem from the symp-
tomatic side it addresses it at the source.” (U5)
Some participants believed that gene drive mos-
quitoes could be better than alternatives in reaching 
hard-to-reach, poorer communities because they could 
bypass the need for human involvement:
“There are other tools that have been brought up 
lately, mosquito nets, malaria drugs, but they have 
turned out to be not very effective because of the 
conception of the people. That’s why [gene drive] has 
been introduced, with the thinking that when they 
let the mosquito out, a particular type of mosquito 
with some effect, it will do its work without even the 
knowledge of the community people.” (U8)
For others, the ability for gene drive mosquitoes to 
reach hard-to-reach, poorer communities meant that 
those with little resources would benefit from malaria 
reduction or elimination.
“For Africa, which is very rural, where 80% of the 
population who live in the rural areas cannot access 
these chemicals for spraying to deal with a vector 
like malaria among mosquitoes, they are constantly 
going down with malaria. They don’t have medicine. 
As the [mosquito] population declines, the people 
are made free from the disease and they are more 
Table 1 Ugandan stakeholders’ hopes and concerns for gene drive mosquitoes for malaria control




Another  possible 
tool in the 
fight against 
malaria
Ability of gene drive mosquitoes to address malaria Lack of public and political support hinders development and deployment












Impacts of gene drive testing and deployment Ecological impacts
Decrease in non-target organisms and/or species diversity as the elimination 
of the mosquito species reverberates through ecosystem
Gene drive construct spreads to, and negatively impacts, non-target organ-
isms through vertical or horizontal gene transfer
Human health impacts
Emergence of new diseases and/or increase in the prevalence of existing 
diseases
Negative impacts on human health
Socio-economic impacts
Negative impacts on the economy and society
Costs and benefits unfairly distributed
Governance of gene drive mosquitoes Novelty and irreversibility
High risk of irreversibility, uncertainty and lack of experiences create govern-
ance challenge
Excitement and hype crowd out alternative approaches to malaria reduction
Inter-state relations
Political conflict between neighbouring African nations
Institutional uncertainty
Unclear regulatory pathway and lack of regulatory capacity
Lack of transparency and independence
Lack of clarity on liability and responsibility
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productive. They are also productive in the sense 
that they don’t fall sick, spend their little resources 
on drugs, because there’s something controlling the 
population of the enemy. So I think this technol-
ogy can be used in the situation where you have the 
poorest of the poor being the key beneficiaries.” (U9)
The ability of gene drive mosquitoes to reduce or elimi-
nate malaria was not only the overriding hope but also 
a source of concern about the possible failure of gene 
drive to reduce or eliminate malaria. This concern has 
two sub-themes. The first and dominant sub-theme was 
that gene drive does not reduce malaria because a lack of 
public and political support hinders its development and 
deployment (U1-3, U5, U8-9, U15-16, U18). The most 
significant barrier was seen to be public suspicion or fear 
of new technologies and of GMOs specifically:
“One of the major challenges [gene drive] faces is 
the acceptability from the public, the public opinion 
goes way against it. There is a lack of understanding 
by the community on exactly what biotechnology is 
and what it does. Most of them are benefiting from 
the products but if you introduce the same products 
and say this is what you are consuming, very many 
of them would reject.” (U15)
Factors such as strict liability clauses that allocate lia-
bility to the developers of technology were seen as strong 
disincentives for development of a transformative tech-
nology. Participants were concerned that public or politi-
cal suspicion—and a failure to allay it—would foreclose 
a transformative technological trajectory to address 
malaria:
“I’m convinced that gene drive is a sure way of elimi-
nating malaria, it’s a sure way … Now if it is exposed 
to the laws that have restricted the other GMOs it 
might cut us from having the sure way of eliminat-
ing malaria. It has been very hard to convince these 
bodies to implement it here … Even if we know the 
results will be good, it can be stopped.” (U8)
The second subtheme to emerge is that gene drive mos-
quitoes do not reduce malaria because the technologi-
cal intervention is ineffective (U2, U4, U5, U6, U7, U13, 
U15). For instance, resistance to the trait or the drive may 
develop, removing the mosquitoes may reduce the eco-
logical burden placed on other malarial vectors, or the 
environmental fitness of the modified mosquitoes may 
be too poor to be sexually competitive, meaning that the 
trait would not spread:
“Malarial mosquitoes are so different depending on 
where it is. I hope those are Ugandan type mosqui-
toes that were from here and you’re just deploying 
them back because if you bring another – it’s like 
when you bring Friesians [cattle], which do well in 
Europe, cold nice temperature, put them here… 
they’ll just go down, they find disease.” (U6)
Theme 2: Impacts from gene drive testing and deployment
Stakeholders identified a variety of hopes and concerns 
related to the potential impacts of testing and deploy-
ment of gene drive technology to address malaria which 
fell into three sub-themes. The most frequent of these 
was potential ecological impacts of a gene drive mosquito 
(U1-8, U10-16, U18). Here, concerns largely fell into two 
sub-categories: 1) a decrease in non-target organisms 
and/or species diversity as a result of the reduction in 
mosquitoes, and 2) potential negative ecological impacts 
as a result of the gene drive construct spreading through 
vertical or horizontal gene transfer. Participants often 
articulated concerns about the impacts on non-target 
organisms and species diversity in the specific Ugandan 
setting, pointing to the importance of local context when 
identifying priorities for risk assessment:
“We have animals that feed on mosquitoes, what 
will those animals feed on? In Uganda, bats and 
chameleons, so they might also disappear.” (U8)
Although acknowledged as relatively unlikely, partici-
pants also identified as a concern the potential for the 
gene drive construct to move across species:
“These genes are not just passive… Hopefully it 
doesn’t jump from one phylum to another one, using 
all kinds of variation. They’re not supposed to, but 
genes can find their way through all kinds of ways 
and you find them going there. So untargeted organ-
isms receiving these novel sets of genes and what 
happens to them will continuously be [the] question.” 
(U6)
While this sub-theme of ecological impacts was domi-
nated by concerns, some participants were hopeful about 
the ecological impacts too, pointing out that gene drive 
mosquitoes were preferable because they will have less 
environmental impact than chemical pesticides:
“If we can have a biological method of control in the 
form of gene drives, you will find out that there is less 
need for harmful pesticide, which has a myriad of 
consequences. Environmentally, you have reduction 
of beneficial organisms like bees getting colony col-
lapse disorder when you use less pesticide. As well, 
you use less energy in the creation of these pesticides, 
and you can reduce your carbon footprint because 
you have less need for actually making those types of 
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pesticides.” (U19)
Many participants also articulated concerns involving 
human health impacts (U2, U4, U6, U8, U11, U13-17). 
These concerns predominantly fell into two sub-catego-
ries: 1) an increase in new diseases and/or the preva-
lence of existing diseases, and 2) a general concern 
about potential negative impacts from gene drive mos-
quitoes on human health. For instance, one participant 
expressed concern about how a replacement gene drive 
could potentially lead to other diseases:
“Maybe they become efficient vectors of another 
disease that was not a problem, and then yes you 
dealt with the malaria, it’s no more, but you have 
made them now transmit something else that you 
get.” (U4)
Participants also discussed how a potential increase 
in malaria prevalence could result from the interaction 
of different mosquito species in the Ugandan context. 
One participant expressed concern about how a gene 
drive-caused decrease in one mosquito species could 
lead to the competitive release of another mosquito 
species that is also a malaria vector, thereby not result-
ing in a reduction in malaria:
“In Uganda the most common vector which is 
responsible for over 70% of malaria transmission 
is the Anopheles gambiae. So that is why we were 
saying that the other vectors do not thrive as well 
as the Anopheles gambiae. So the possibility that 
the Anopheles gambiae causes a burden, an eco-
logical burden on the other vectors, so that if you 
remove it then the others will thrive. So that might 
not favor our ultimate aim of reducing malaria 
transmission.” (U2)
Participants also stated general concerns about 
gene drive impacting human health. One partici-
pant described a concern about whether a gene drive, 
designed to impact the genome of an entire species, 
could end up impacting the human genome.
“So, I think the fear is the unknown probably at 
this stage… If you can affect the mosquito genome, 
can it affect the human genome?” (U11)
Another participant shared a general concern about 
the impact of a gene drive on human health because 
of the interconnectedness of humans and their 
environment:
“Human beings by their nature use what is in the 
environment for survival, food, everything, so 
whatever comes in that ecological set-up ends up 
in the human body, one way or the other. So that is 
another angle that some people raise issues about, 
and perhaps that’s what scares people most.” (U14)
The third sub-theme involves hopes and concerns 
about the potential socio-economic impacts, particu-
larly potential changes to established social, cultural 
and economic practices and organizations resulting 
from the development or deployment of gene drive 
mosquitoes. Stakeholders raised a wide range of con-
cerns beyond human health and environmental risk 
(U1-2, U5, U7-8, U10, U13-14, U16):
“This issue of gene drive is not just about science, 
it’s about human rights, it’s about social cultural 
aspects.” (U10)
The specific issues raised were diverse including 
potential impacts on the communities living around 
test sites, with one participant questioning whether 
Ugandans were being used as guinea pigs (U2). Another 
participant suggested that inadequate consideration 
and management of community relations could result 
in an exodus from these villages. Others were con-
cerned with the impact of gene drive on entities that 
were central to Ugandan identity. For instance, when 
asked about the social impacts of gene drive use, one 
participant raised concerns about the effect on Lake 
Victoria, which has significant cultural as well as eco-
nomic importance to Ugandans (U10). Several par-
ticipants were concerned with the economic impacts 
of using gene drive to successfully eradicate malaria, 
emphasizing that while it may be a worthy goal there 
would be large-scale social and economic change, and 
within that change there would be losers as well as 
winners:
“There are many people surviving on malaria, sell-
ing drugs, malaria pesticides to control mosquitoes 
and all those would be jobless and that would disor-
ganize the world.” (U1)
A related and shared concern was with the distribution 
of benefits. Instead, they suggested that the primary ben-
eficiaries might be the scientists developing the technolo-
gies, who might publish and gain academic credentials, 
and raised concerns about whether local communities 
would benefit (U16). Drawing on a history of past devel-
opment projects, one participant emphasized,
“We have seen a lot of scientific innovations that 
have not benefitted the people, young or old and all 
of those kind of things. We have seen them but they 
have not benefitted the people.” (U13)
However, some participants highlighted possible socio-
economic benefits (U3, U5-7, U14, U18). Participants 
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pointed to possible increases in productivity and cost-
savings for the Ugandan, regional and local governments 
and individual households.
“Less malaria, less death will affect the economy and 
the health of the people, because we know malaria is 
a really big budget in our country” (U18)
“You would think the cost for malaria control, which 
is so heavy on government would go down, would go 
down for householders as well” (U14)
Theme 3: Governance of gene drive mosquitoes
There was widespread and persistent concern that gene 
drive mosquitoes are a particularly difficult technology 
to govern (U1-6, U8-11, U13-16, U18). Central to this 
concern was the novelty and irreversibility of gene drive 
mosquitoes (U1-7, U10, U13-16). The majority of partici-
pants were concerned about the novelty and potential for 
irreversible damage from the technology’s development 
and potential use that raised significant ethical concerns 
for governance:
“That is a huge ethical consideration because this 
is something that is happening for the first time, we 
have never done this, we haven’t done the risk assess-
ments that you want to release the genetically modi-
fied mosquito with gene drive into the community, 
what impact does it have? These are ethical issues.” 
(U2)
Participants suggested that irreversibility makes risk 
governance particularly challenging:
“It means we will need to clearly undertake labora-
tory understanding and modelling to be critically 
sure before even being released. Because once it 
comes out to the community there is no way you can 
take that back.” (U15)
For some participants, novelty and irreversibility justi-
fied a careful and cautious approach to governance:
“Sometimes it’s good to be a guinea pig. But so if we 
don’t have a case study [of gene drive deployment 
to learn from], then we have a problem that we just 
have to go in blind, normally you have to be cau-
tious… It’s not like it’s a matter of life and death 
right now. Even if we didn’t put the gene drives here, 
we still have our usual way that has kept malaria 
down. At some point, you’re measuring, you’re 
weighing between our usual way which we use to 
control malaria and a totally new approach. You 
don’t rush to these new approaches.” (U6)
Other participants cautioned against seeing gene drive 
mosquitoes as a technological ‘silver bullet’ to the prob-
lem of malaria. Doing so could lead to effective, less risky, 
alternatives being overlooked:
“So, for me, I feel that this is an experimental tech-
nology and we should not be distracted, because 
there are other countries that have eradicated 
malaria without the need of techno fixes. I’ll give 
you two examples, Sierra Leone and Paraguay 
have eradicated malaria without gene drives. So 
I think we need to learn from them what they are 
doing right and how those lessons can be extrapo-
lated to Uganda, yeah.” (U10)
The second governance sub-theme to emerge is the 
importance of inter-state relations, concerning the 
international nature of gene drive development and, 
particularly, an inability to contain or recall gene drive 
mosquitoes across national borders (U1-4, U6, U9, 
U10, U12-14, U16-18). Two participants believed the 
visible success of gene drive would defuse any poten-
tial conflicts while another raised a concern that other 
countries may benefit from a Ugandan technology (a 
gene drive mosquito) without paying. However, the 
majority of participants were concerned that gene drive 
mosquitoes’ characteristics had the potential to create 
inter-state conflict:
“I think the risks are not technical risks of the bio-
logical phenomenon; they are risks of cross-border 
interaction with the people… For example, you 
may find that a new disease has broken out in a 
neighbouring country which did not deploy the 
gene drive, and the people, through rumors, will 
attribute that phenomenon to the gene drive that 
was released.” (U9)
For these reasons, some participants argued that a 
regional approach to governance was needed, sup-
ported by public engagement and acceptance:
“Humans will need visas and passports to cross 
borders but mosquitoes don’t need passports, they 
don’t need visas to cross borders. So… if there is a 
field release and we will not be able to control the 
dispersion of these mosquitoes, modified mosqui-
toes, which have a gene drive attached to it, we will 
not be able to recall or control the trans-border 
spread … Yes, that is a genuine concern and I think 
it is a question of engagement, how well we engage, 
and then also a question of acceptance of this tech-
nology, and that cannot be predetermined.” (U2)
The final sub-theme is institutional uncertainty (U1-
7, U10, U13-14, U16) in which participants questioned 
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the legal, organizational and procedural capacity neces-
sary for gene drive governance as well as potential con-
flicts of interest. Some participants questioned whether 
Uganda had the capacity to independently appraise 
gene drive mosquitoes:
“Unfortunately … we’re still trying to understand 
first generation GMO and gene drives is already 
second generation with very sophisticated technol-
ogies, like CRISPR. Our law, as it stands, I don’t 
think we’ll be able to regulate gene drives, as they 
are, because we’ve not yet even understood, we 
don’t even have an elaborate functioning biosafety 
framework.” (U10)
Other participants pointed to the lack of scientific 
capacity in Ugandan institutions to adequately address 
novelty and complexity of gene drive:
“The other point is on capacity, capacity within 
the country to actually monitor, to effectively guide 
the policymakers about this. Because, at any given 
moment the policymakers may not be scientists, or 
even scientists, not every scientist is a geneticist.” 
(U14)
Governance concerns were compounded by a per-
ceived lack of transparency and independence of regu-
lators from gene drive developers:
“The people who are promoting these technologies 
are the same people who want to regulate them. So 
I don’t think that it’s an impartial situation.” (U10)
“It really is still a very new concept for most of us 
in Uganda … Scientists may be able to share when 
they’re doing this but sometimes the information 
they share is not complete information in the sense 
of there are people going to be affected by this tech-
nology may not necessarily be the ones that will be 
consulted and they may not get an opportunity to 
understand how this gene drive is going to affect 
them … so there is a bit of scientists not being very 
transparent’ (U16)
Many participants called for the early involvement of 
a broader range of actors in governance decisions and 
new institutions that could address the ethical as well 
as the scientific risks raised by gene drive mosquitoes:
“People really need to know what the ethics are of 
course what the positives, the pros and the cons 
that they are fully aware of, you know what is 
being introduced into the country.” (U16)
“We need a multidisciplinary committee or team 
that is going to regulate these technologies in the 
country and not just with it being seen as a scien-
tific issue.” (U10)
Several participants believed liability and responsibility 
were essential for good governance yet there was uncer-
tainty as to whether adequate frameworks were in place:
“First there have been issues on liability, issues to do 
with liability, who is liable if anything goes wrong, 
who takes responsibility. That has been a major con-
cern.” (U2)
Discussion
This is the first study of stakeholders’ hopes for and con-
cerns about gene drive mosquitoes as a novel approach 
to malaria control in Uganda, where Target Malaria is 
preparing for field trials. Findings reveal hopes over-
whelmingly focused on reducing or eradicating malaria 
along with some mention of the socio-economic benefits 
of reducing malaria, while concerns were spread across 
three areas—concerns that malaria may not be reduced, 
possible negative impacts from the technology and ques-
tions about how the technology would be governed.
Expanding the scope of risk regulation
High-level, collaborative governance documents pre-
scribing risk governance frameworks for gene drive 
organisms recognize that engaging with social-cultural 
contexts is needed for the development and testing of the 
technology [20]. For example, Roberts et al. [12] note that 
definitions of biodiversity risk are dependent on ‘what 
aspects of biodiversity are considered valuable’ and call 
for the inclusion of values that reflect the social and cul-
tural context. This study demonstrates that local stake-
holders are able and willing to contribute relevant and 
important knowledge to the development of risk frame-
works. For example, the ecological and human health 
concerns identified by the participants closely align with 
the risk categories identified by world-leading experts 
in the European Food Safety Authority (EFSA) Panel on 
Genetically Modified Organisms during an investiga-
tion into the adequacy of existing guidelines for the risk 
assessment of gene drive insects [7]. While stakeholders’ 
concerns aligned with EFSA risk categories, they were 
articulated in more detail, reflecting the local social, cul-
tural and environmental context and helping to identify 
environmental protection goals.
Previous research demonstrates that stakeholders 
see the risks of biotechnologies more broadly than do 
science-based regulatory agencies, which focus almost 
exclusively on environmental and human health risks [32, 
33]. This study shows that in addition to situating risk 
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in the local context, stakeholders raised a broader set of 
concerns about gene drive mosquitoes than those consid-
ered in traditional regulatory frameworks. In particular, 
they are concerned about the socio-economic impacts 
and governance frameworks for gene drive mosquitoes. 
The incorporation of socio-economic considerations in 
regulatory frameworks is contentious and there are few 
examples of frameworks that have specified what counts 
as a socio-economic consideration or successfully inte-
grated them into risk decision-making [32]. However, 
attentiveness to these considerations will be important 
for the ethical justifiability and social acceptability of risk 
decisions concerning the testing and deployment of gene 
drive mosquitoes [34].
Identifying and assessing the benefits of gene drive 
solutions to malaria control
There is strong support from developers, funders and 
others for considering the potential benefits of gene drive 
in risk governance decisions in Africa [35]. For example, 
AUDA [2] promotes the importance of considering bene-
fits and advocates the use of risk/benefit analysis in deci-
sions about the use of gene drives which involve weighing 
up the human health benefits of malaria reduction or 
eradication against the environmental and biodiversity 
risks. This study shows the range of benefits that Ugan-
dan stakeholders envisage but it also highlights a range of 
concerns about how these benefits might not be realized, 
showing their contingency. In the case of gene drive mos-
quitoes for malaria control in Uganda, decision-makers 
will have to make a trade-off between the human benefits 
of malaria eradication and environmental risk.
Yet while considerable empirical and theoretical work 
is going into assessing the risks, very little if any work is 
being done the assess the benefits in a substantive way. 
For example, Carter and Friedman [36] state: ‘The benefits 
are clear if these research efforts are successful; however, 
the risks must first be carefully evaluated’ and a more 
recent report argues ‘In spite of all of these valuable bene-
fits, there must be careful consideration of risks associated 
with gene drives’ [37]. Each of these examples takes the 
benefits as self-evident. However, as with risks, benefits 
(and the conditions that are necessary to realize them) 
will need to be considered in the local context. That is, 
effort needs to be made to identify the benefits that 
could, or are likely to result, and also assess the social, 
political, economic, ecological and technical conditions 
that need to occur for those benefits to be realized. With-
out such consideration, technical optimism  may make 
the assumed benefits seem more likely than they are.
Underlying the call by developers and funders to con-
sider potential benefits is the perception that a focus on 
assessing risks without considering benefits will favor 
restrictive field testing designs [38]. There is a danger that 
given the huge investments in regulation development 
by the BMGF and other philanthropists, benefits will be 
included in order to reduce the risk of restrictive regula-
tions and facilitate the deployment of the technology. For 
example, in 2020, AUDA received US$6 million to ena-
ble the deployment of gene drive mosquitoes for malaria 
control and in 2016, the US Foundation for the National 
Institutes of Health received US$8.3 million to ‘acceler-
ate’ preparations for gene drive mosquitoes in Africa 
[27]. These top-down pressures to facilitate and support 
gene drive make the degree to which Ugandan voices can 
be heard more challenging and may make stakeholder 
hopes for technology and risks of not realizing these ben-
efits less visible.
However, international and regional developments 
can be complemented by the involvement of national 
stakeholders who live with malaria on a daily basis and 
are knowledgeable actors who possess relevant exper-
tise needed to contribute to benefit assessment and the 
exploration of pathways to realize such benefits.
The assessment of benefits and risks is inherently a 
value-based exercise and there are powerful arguments 
for opening up risk decision-making to local actors on 
these grounds in addition to the substantive reasons dis-
cussed above [35, 39]. Decisions which balance benefits 
to human health against possible environmental harms, 
particularly in comparison to other possible solutions 
with fewer risks (i.e. bed nets) are ethical decisions and 
cannot be made without ethical analysis and engagement 
with local communities [40]. Overall, a more integrated 
approach, one that integrates the risks and benefits as 
well as the science and the politics, may help to clarify 
the decisions to be made and the trade-offs between the 
risks and benefits of gene drive solutions to malaria.
New directions for inclusive risk governance processes
An important finding from the study is that the way in 
which gene drive mosquitoes are governed is a source 
of concern for stakeholders. There was a great deal of 
uncertainty about whether existing institutions and gov-
ernance frameworks were sufficient and what the alterna-
tives might be. A decision-making pathway is needed for 
gene drive mosquitoes, clarifying in particular the role 
risk assessment will play and how potential benefits and 
socio-economic factors will be considered in decision-
making. If decisions are based on narrow risk assess-
ments conducted by experts, particularly if these have 
been developed by non-Ugandans, then there is a high 
risk that the decision will be perceived by Ugandan stake-
holders and/or members of the public as illegitimate. A 
decision-making pathway is needed that draws on local 
knowledge and values, garnered through engagement 
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with stakeholders, publics and communities and it should 
not rely on arm’s length public consultations on highly 
technical risk guideline documents produced solely 
through expert-centered processes. International support 
is available through the Cartagena Protocol on Biodiver-
sity which allows States to consider societal concerns 
such as the ethical, social, and economic impacts of gene 
drive mosquitoes in regulatory decisions [32].
Not surprisingly, there is a demonstrable willingness on 
the part of communities and publics to engage with pro-
jects which may reduce or eliminate malaria [3, 4]. Fur-
ther, involving local actors helps to build much-needed 
regulatory and risk decision-making capacity [6, 10]. 
However, engaging with national stakeholders may be 
seen as a distraction from the expert-led risk governance 
activities currently underway at the regional and interna-
tional level. Importantly, local actors are significantly less 
resourced, making it more difficult for their voices to be 
heard, particularly when they may compete with regional 
African Union-led efforts to harmonize risk regulatory 
frameworks which are well-funded by gene drive funders 
and embody powerful beliefs about the importance of 
technology for Africa’s development (Hartley et al, pers. 
commun.). However, stakeholder and community input 
into risk governance processes will help to ensure that 
the development and deployment of the technology is 
conducted in a democratic and deliberative fashion. 
Despite the recognition that traditional forms of engage-
ment in risk regulatory processes will not be sufficient for 
gene drive mosquitoes and calls for rigorous stakeholder 
engagement in regulation and oversight [35, 38], there 
is a lack of concrete thinking in current expert-led risk 
governance activities about how and when stakeholders, 
communities and/or publics can provide input and shape 
the regulatory frameworks that will be designed to pro-
tect them. Recent experiences with regulatory decisions 
to release genetically modified insects in the USA, Brazil 
and Burkina Faso fail to demonstrate meaningful or rig-
orous stakeholder engagement in both the development 
of risk governance frameworks and case-by-case deci-
sions on individual releases [41–43].
Conclusion
Malaria is a global health priority [44]. Aside from the 
obvious and severe health implications, malaria affects 
population growth, saving and investment, worker pro-
ductivity, absenteeism from school, trade and foreign 
direct investment, premature mortality, and medi-
cal costs [44]. Gene drive mosquitos are a cutting-edge 
and promissory approach to vector control for malaria 
control and eradication, which are currently sup-
ported by international and regional actors such as the 
BMGF, AU and the AU’s High-Level Panel on Emerging 
Technologies. To prepare for gene drive mosquito field 
trials, an international process is underway to develop a 
risk governance framework. This framework is impor-
tant as it will outline the way in which decisions about 
whether or not to release gene drive mosquitoes will be 
made and is expected to shape national and regional risk 
decision-making.
Social science research tells us that externally imposed, 
top-down and locally-insensitive approaches to tech-
nology introduction and development in Africa are 
problematic and can limit a technology’s potential to 
serve its intended goals [45, 46]. International processes 
to develop risk governance frameworks can provide 
high-level guidelines but risk decision-making must be 
grounded in the local context and involve local stakehold-
ers, communities and publics if it is to be robust, mean-
ingful and legitimate. This type of engagement should 
accompany and complement (not replace) the commu-
nity engagement work necessary for gaining a commu-
nity’s prior, free and informed consent to participate in 
or host field trials [47]. In a modest step, this study brings 
Ugandan voices into the discussion about the hopes and 
concerns for gene drive mosquitoes which are planned to 
be released in field trials in Uganda. The data shows the 
importance of assessing the benefits and socio-economic 
impacts in collaboration with stakeholders and commu-
nities, and delineating a clear decision-making pathway 
that includes engagement, conducted by regulators and 
decision-makers and recognizing the value decisions 
involved. Decisions about whether or not to release gene 
drive mosquitoes will need to consider the assessment of 
both the risks and the benefits of gene drive mosquitoes 
for malaria control within a particular social, political, 
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